Clinical trial NCT01354717: Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo
Official title: Phase 3 Study of Brand Generic and Placebo in Treatment of Actinic Keratosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Actinic Keratoses
Lead sponsor: Spear Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2011-05-17
Enrollment: 377
Sex: ALL
Minimum age (years): 45
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a double-blind, randomized, placebo-controlled, three treatment parallel study in which normal, healthy men and women (age 45-85) with actinic keratosis will be treated on the face once daily for two weeks with 5-Fluorouracil Cream 0.5%, Spear Pharmaceuticals (Generic), Carac® Cream 0.5% (Brand), or Cream Vehicle (Placebo). Actinic keratoses will be counted at the baseline visit and at the visit four weeks following cessation of treatment.

Detailed description: actinic keratosis

Eligibility criteria: Inclusion Criteria:

Men and women with the presence of actinic keratoses

* Women who have had surgical sterilization or are post-menopausal (absence of menses for at least one year) are eligible. Women of child-bearing potential who are non-pregnant and non-nursing, and willing to avoid pregnancy during the course of the study and during the menstrual cycle following completion of their participation in the study are eligible. (Adequate contraception is defined as regular use of, diaphragm with condoms, IUD with condoms, or systemic contraceptives - if used for at least three months prior to enrollment in the study). A negative pregnancy test is required at entry into the study
* Able to refrain from the use of all other topical medications to the facial area during the treatment period
* Considered reliable and capable of understanding their responsibility and role in the study
* Have provided written informed consent

Exclusion Criteria:

* History of allergy or hypersensitivity to 5-fluorouracil

  * Known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency
  * Clinical evidence of severe, uncontrolled auto-immune, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, pulmonary or renal disease
  * Dermatologic conditions if present on the face such as: atopic dermatitis, basal cell carcinoma, eczema, psoriasis, rosacea, squamous cell carcinoma, or albinism
  * Positive urine pregnancy test in women of child-bearing potential
  * Inability to use adequate birth control measures for women of child-bearing potential, as defined above
  * Serious psychological illness
  * Significant history (within the past year) of alcohol or drug abuse
  * Participation in any clinical research study during the 30 day period preceding study initiation
  * Medical history which, based on the clinical judgment of the investigator, implies an unlikelihood of successful completion of the study
  * Treatment for actinic keratosis or skin cancer in the previous 28 days with the following: topical 5 fluorouracil, cryodestruction (liquid nitrogen spray), curettage (scraping of pre-cancer or skin cancers), surgical removal of skin cancer, photodynamic therapy, surgical excision, topical diclofenac (Solaraze), topical imiquimod (Aldara), topical retinoids if used for actinic keratosis or other treatments for actinic keratoses
  * Application of 1) chemical peel, 2) dermabrasion, 3) laser abrasion, 4) PUVA (psoralen plus ultraviolet A) therapy, or 5) UVB therapy to the face or bald scalp within six months prior to randomization
  * Use of sun lamps or sun tanning beds or booths during the 2 weeks prior to first application until Day 42 visit
  * Any oral (systemic steroids) or topical corticosteroids within 1 month of study entry, except for subjects on chronic low dose corticosteroids less than 5 mg daily for greater than 1 year
  * Use within 1 month of any immunomodulators like interferon, or cytotoxic drugs
  * Prior treatment with systemic 5-fluorouracil or systemic cancer therapy within 6 months of study entry
  * Subjects with lesions suspicious for squamous cell carcinoma

Primary outcomes:
measure: Percent of patients with clearing
timeFrame: August 28, 2010 to March 17, 2011
measure: Clearing of actinic keratosis
timeFrame: 42 days
Secondary outcomes:
measure: superiority to placebo
timeFrame: 42 days
Other outcomes:
measure: Irritation
timeFrame: 14 days
Locations:
Study officials:
affiliation: Alliance Clinical Research, Inc
name: Melanie Appell, M.D.
role: PRINCIPAL_INVESTIGATOR
References: